SNDX - What's Going On With Leukemia-Focused Syndax Pharmaceuticals Stock Today? | Benzinga
Syndax Pharmaceuticals Inc (NASDAQ: SNDX) shares are trading higher after the company shared data from multiple trials of revumenib in combination with standard-of-care agents in patients with nucleophosmin mutant (mNPM1) and KMT2A-rearranged (KMT2r) relapsed/refractory (R/R) acute leukemias.
AML trial of revumenib in combination with venetoclax-decitabine/cedazuridine in R/R AML was featured during an oral session at the 65th American Society of Hematology (ASH) Annual Meeting.
As of a data cutoff date of November 1, ...